Low dose Azanucleosides for high risk (s)MDS and AML

P.W. Wijermans

doi:10.4081/hmr.v2i15.613

Abstracts

16 June 2009

Vol. 2 No. 15 (2006)

https://doi.org/10.4081/hmr.v2i15.613

Low dose Azanucleosides for high risk (s)MDS and AML

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

219

Views

252

Downloads

Authors

P.W. Wijermans

support@pagepress.org

Azanucleosides like 5-aza- 2’deoxycytidine (Decitabine= Dacogen) and 5-azacytidine (Vidaza) are both cytosine analogues, already synthesised in1964, tested for there cytotoxic capacity when applied in high doses. Using high dose Decitabine therapy for AML patients it became clear that there was a good antileukemic activity but also a high toxicity.